January 25, 2015 9:43 PM ET


Company Overview of CorePharma, L.L.C.

Company Overview

CorePharma, L.L.C. develops, manufactures, and markets generic and branded prescription pharmaceuticals in the United States. The company offers its products in various dosage forms, such as oral tablets, capsules, and pellet dosages, as well as in various therapeutic categories. It manages a portfolio of high barrier-to-entry products that include controlled substances, which include Schedule-II, -III, –IV, and –V drugs; and modified release formulations. The company was founded in 1998 and is based in Middlesex, New Jersey.

215 Wood Avenue

Middlesex, NJ 08846

United States

Founded in 1998





Key Executives for CorePharma, L.L.C.

Chief Executive Officer
Chief Financial Officer and Senior Vice President
Senior Vice President of Operations
Chief Scientific Officer and Vice President of Research & Development
Senior Vice President of Quality
Compensation as of Fiscal Year 2014.

CorePharma, L.L.C. Key Developments

Amedra Pharmaceuticals LLC, CorePharma, L.L.C., Impax Laboratories Inc., Lineage Therapeutics Inc., Tower Holdings, Inc. - M&A Call

To discuss the acquisition transaction between company and Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc

Hikma Pharmaceuticals Reportedly Eyeing $1 billion Bid For Corepharma

Hikma Pharmaceuticals plc (LSE:HIK) is reportedly looking at buying CorePharma, L.L.C. for up to $1 billion from RoundTable Healthcare Management, LLC. CorePharma was reportedly put up for sale in August and Hikma is now one of a number of bidders for the firm. Barclays and HSBC are both said to be lined up to provide debt financing for Hikma should a deal be agreed. Credit Suisse is thought to be handling the auction process. Hikma and CorePharma both declined to comment.

CorePharma, LLC Announces the Launch of Dextroamphetamine Sulfate Tablets, USP

CorePharma, LLC announced that it has launched Dextroamphetamine Sulfate Tablets, USP, the generic version of Shire's Dextrostat(R). Dextroamphetamine is indicated for the treatment of narcolepsy and attention deficit disorder with hyperactivity. CorePharma received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) on March 7, 2014. The product is available in the 5 and 10mg strengths and has begun shipping.

Similar Private Companies By Industry

Company Name Region
Fujifilm Diosynth Biotechnologies United States
Nutrition Formulators, Inc. United States
Acpharis Inc. United States
Parker Hughes Cancer Center United States
Raritan Pharmaceuticals Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CorePharma, L.L.C., please visit www.corepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.